Fungal infection and vision impact in patients with diabetic eye disease

News
Article

Rhino-orbital-cerebral mucormycosis, a life-threatening fungal infection, typically occurs in patients with diabetes

A brain and a fungus mushroom both depicted in illustration. Concept image for fungal infection and diabetic eye disease. Image credit: ©Anson – stock.adobe.com  – generated with AI

Image credit: ©Anson – stock.adobe.com – generated with AI

A recent report published by Turkish investigators showed that mucormycosis infection should not be overlooked in the differential diagnosis in patients with diabetes who present with sudden vision loss and cranial nerve palsies,¹ according to Irem Sena Sarac, MD, first author and ophthalmology resident in the Department of Ophthalmology, Prof Dr Cemil Tascioglu Sehir Hastanesi City Hospital, Istanbul.

Sarac and colleagues explained that rhino-orbital-cerebral mucormycosis (ROCM) is a severe, life-threatening fungal infection caused by opportunistic fungi of the order Mucorales, most often Rhizopus oryzae.2 This infection typically occurs in patients with diabetes or those who are immunocompromised.

The fungus spores can be inhaled or enter the body through sites of burns or trauma.2,3 Uncontrolled diabetes, haematologic malignancies and immunosuppressive therapy are the major risk factors for ROCM infection.3,4 Once established in the body, the results are often vascular thrombosis and tissue necrosis.4 The most common clinical presentations of mucormycosis are ROCM and pulmonary mucormycosis.5

ROCM case

A woman aged 64 years with diabetes arrived at the emergency department reporting dizziness, headache, and decreased vision in the left eye that had persisted over the course of 1 week.

On initial examination in the ophthalmology department, the best-corrected visual acuities in the right and left eyes, respectively, were 6/60 and no light perception.

Although the anterior chamber of the right eye was normal, funduscopy showed retinal haemorrhages and exudates consistent with diabetic retinopathy and the optic disc appeared normal.

The pupil in the left eye was nonreactive to light. Ptosis, mild proptosis and chemosis in the left eye were observed, with no eyelid oedema or hyperaemia. The extraocular motility of that eye was limited in all directions. The anterior segment was normal. Fundus examination showed optic disc oedema, retinal haemorrhages and exudates consistent with diabetic retinopathy, and retinal pallor with a cherry-red spot at the fovea consistent with central retinal artery occlusion. On day 2 of hospitalisation, eyelid oedema and hypaeremia developed in the left eye.

Laboratory testing showed leukocytosis with neutrophil predominance, elevated C-reactive protein, hyperglycaemia and elevated hemoglobin A1c. Noncontrast orbital and paranasal sinus computed tomography scans showed left orbital cellulitis, proptosis and severe ethmoidal and maxillary sinusitis.

R oryzae was identified by histopathologic examination. No black necrotic tissue was apparent in the nasal and sinus mucosa and skin. Blood cultures showed no growth. Cranial magnetic resonance imaging showed maxillary and ethmoidal sinusitis and increased T2 signal intensity surrounding the left optic nerve, consistent with inflammation, the investigators described.

Management included antifungal treatment (i.e., increasing dosages of liposomal amphotericin B), left orbital exenteration and endoscopic sinus surgery. One week after exenteration, the C-reactive protein value decreased, and a week later, imaging showed progressed sinusitis followed by another sinus surgery, after which the disease stabilised.

The next round of blood cultures grew pan-resistant Klebsiella and Pseudomonas aeruginosa, and acute renal failure ensued.

During follow-up, no signs of infection or inflammation were observed in the right eye or orbit. Despite intensive treatment and surgery, the patient died on day 64 of the hospitalisation.

Sarac and colleagues commented, “Mucormycosis is an angiotropic fungal infection that invades the internal elastic lamina of blood vessels, leading to angioinvasion, haemorrhagic necrosis and vascular thrombosis, particularly affecting arteries, veins and lymphatics, through both mechanical compression and toxin-mediated damage.6 Vision loss may be due to central retinal artery occlusion or orbital apex involvement affecting the optic nerve function.6 In our case, central retinal artery occlusion was suspected to have occurred either due to compression of the ophthalmic artery from soft tissue invasion of the orbital apex or as a direct result of angioinvasion by the fungus.”

Considering this patient’s course, the investigators concluded, “Mucormycosis infection should be considered as a differential diagnosis in diabetic patients presenting with sudden vision loss and cranial nerve palsies. Mucormycosis is a rapidly progressing, devastating infection that requires rapid diagnosis and management by a multidisciplinary team.”

References

  1. Sarac I, Aksu Y, Yildiz D, et al. Rhino-orbital mucormycosis presenting with central retinal artery occlusion: a case report. Cureus.2025;17:e88020. doi:10.7759/cureus.88020.
  2. Katsitadze L, Javakhishvili G, Burkadze G, et al.Mucormycosis in a diabetic patient: a case report from Georgia. Cureus. 2024;16:e69399.10.7759/cureus.69399
  3. Bitar D, Van Cauteren D, Lanternier F, et al.Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis.2009;15:1395-401.10.3201/eid1509.090334
  4. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13:236-301.10.1128/CMR.13.2.236
  5. Benlamkaddem S, Zdaik G, Doughmi D, et al.Rhino-orbital cerebral mucormycosis: a fatal evolution. Cureus. 2023;15:e37837.10.7759/cureus.37837
  6. Sethi NK, Chadha C, Bajaj M, Moond H. Central retinal vein occlusion as primary ocular manifestation of rhino-orbital-cerebral mucormycosis: A case report. Indian J Ophthalmol. 2022;704451-3. DOI:10.4103/ijo.IJO_1318_22

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.